Kodiak Sciences Inc.

NASDAQ:KOD

Biotechnology

Healthcare
$97.81 -0.08%

-$0.03 today

Market cap
$6.40B
Beta
2.21
P/E (TTM)
-9.6
EPS (TTM)
-$3.73
52W Low $3.43High $47.84

Volume 0.74M

Average 1.10M

KOD Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Kodiak Sciences Inc.NASDAQ: KOD

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables outflow grows to $0

Q3 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How KOD compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
KOD Competitors
Accounts Receivables for KOD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$968.8M USD-888.3%-11.1%6.2%
BLCOBausch + Lomb CorporationLTM Jun 2026$89.24M USD+37.3%+15.9%1.7%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$19.05M USD-355.9%+58.8%250.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$968.41K USD——290.7%
OCULOcular Therapeutix, Inc.LTM Mar 2026$874K USD-34.0%—1.7%
OCSOculis Holding AGLTM Mar 2026CHF 272.05K CHF-142.6%—54.0%
BLTEBelite Bio, IncLTM Jun 2026$60 USD—+27.3%—
KODKodiak Sciences Inc.LTM Sep 2026$0 USD———
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
OCGNOcugen, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding KOD) —-142.6%+21.6%4.0%

Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Depreciation & Amortization8.71M11M25.95M26.71M26.32M
Deferred Income Tax00000
Stock-Based Compensation61.39M106.03M88.56M60.21M58.86M
Change in Working Capital14.43M11.96M(7.36M)(28.39M)6.85M
Accounts Receivables00000
Inventory00000
Accounts Payables(2.09M)1.66M5.6M(9.69M)8.07M
Other Working Capital16.52M10.3M(12.95M)(18.69M)(1.22M)
Other Non-Cash Items198K(1.63M)(840K)355K1.93M
Operating Cash Flow(182.27M)(206.46M)(154.18M)(117.32M)(136.01M)
Capital Expenditures(63.3M)(47.36M)(41.43M)(400K)(506K)
Acquisitions (Net)00(290.65K)00
Purchases of Investments0(427.77M)(49.35M)(355K)0
Sales of Investments24.5M138M340M00
Other Investing Activities0616K290.65K00
Investing Cash Flow(38.8M)(336.51M)249.23M(755K)(506K)
Debt Repayment00000
Common Stock Issued8.23M1.94M242K501K178.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(45K)(49K)(211K)00
Financing Cash Flow8.18M1.9M31K501K178.3M
Effect of Forex Changes00000
Net Change in Cash(212.89M)(541.08M)95.07M(117.57M)41.79M
Free Cash Flow(245.57M)(253.82M)(195.61M)(117.72M)(136.51M)

Kodiak Sciences Inc.

NASDAQ:KOD

Intrinsic Alpha fair value

Locked

Current Price

$97.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.